The IL-6/IL-6R/sgp130 system and Th17 associated cytokines in patients with gestational diabetes

Endokrynologia Polska

Volumn 65, Issue 3, 2014, Pages 169-175

  Kuźmicki, Mariusz ^a   Telejko, Beata ^a   Lipińska, Danuta ^a   Pliszka, Justyna ^a   Wilk, Juliusz ^a   Wawrusiewicz Kurylonek, Natalia ^a   Zielińska, Anna ^a   Sobota, Angelika ^a   Krȩtowski, Adam ^a   Górska, Maria ^a   Szamatowicz, Jacek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Gestational diabetes; Gp130; IL 17; IL 23; IL 6; IL 6R

Indexed keywords

GLUCOSE; GLYCOPROTEIN GP 130; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TRIACYLGLYCEROL; IL17A PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CHILDBIRTH; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PROTEIN BLOOD LEVEL; TH17 CELL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METABOLISM; PREGNANCY; RISK FACTOR; YOUNG ADULT;

ADULT; CYTOKINE RECEPTOR GP130; DIABETES, GESTATIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; PREGNANCY; RISK FACTORS; TH17 CELLS; YOUNG ADULT;

EID: 84903594132     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2014.0023     Document Type: Article

References (40)

1. Eder K, Baffy N, Falus A et al. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009; 58: 727-736.
2. Jones SA IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6. Int J Biol Sci 2012; 8: 1237-1247.
3. Jones SA, Richards PJ, Scheller J et al. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005; 25: 241-253.
4. Rose-John S, Scheller J, Elson G et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leuk Biol 2006; 80: 227-236.
5. Knüpfer H, Preiss R. sIL-6R: more than an agonist? Immunol Cell Biol 2008; 86: 87-91.
6. Jostock T, Müllberg J, Ozbek S et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268: 160-167.
7. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J BiolChem 2003; 278: 45777-45784.
8. Lagathu C, Bastard J P, Auclair M et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372-379.
9. Senn JJ, Klover PJ, Nowak IA et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-3399.
10. Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 2004; 47: 1135-1142.
11. Kristiansen O P, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 54: S114-S124.
12. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm 2009; 80: 613-633.
13. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-949.
14. Moseley TA, Haudenschild DR, Rose L et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155-174.
15. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129: 311-321.
16. Hunter CA New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-531.
17. Langrish CL, McKenzie BS, Wilson NJ et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
18. Aggarwal S, Ghilardi N, Xie MH et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of nterleukin-17. J Biol Chem 2003; 278: 1910-1914.
19. Shin JH, Shin D W, Noh M. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem Pharmacol 2009; 77: 1835-1844.
20. Atègbo JM, Grissa O, Yessoufou A et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab 2006; 91: 4137-4143.
21. Kuzmicki M, Telejko B, Zonenberg A et al. Circulating pro- and anti-inflammatory cytokines in Polish women with gestational diabetes. Horm Metab Res 2008; 40: 556-560.
22. Kuzmicki M, Telejko B, Szamatowicz J et al. High resistin and interleu-kin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol 2009; 25: 258-263.
23. Morisset AS, Dubé MC, Côté JA et al. Circulating interleukin-6 concentrations during and after gestational diabetes mellitus. Acta Obstet Gynecol Scand 2011; 90: 524-530.
24. Matsuda M & DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
25. Retnakaran R, Qi Y, Goran MI et al. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 2009; 26: 1198-1203.
26. Stancáková A, Javorský M, Kuulasmaa T et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 2009; 58: 1212-1221.
27. Matthews DR, Hosker J P, Rudenski AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
28. Kleiblova P, Dostalova I, Bartlova M et al. Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus. Mol Cell Endocrinol 2010; 314: 150-156.
29. Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipo-kines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrinol (Oxf) 2012; 76: 2-11.
30. Zieleniak A, Cypryk K, Wozniak LA et al. Adenosine receptors expression is elevated in leukocytes of gestational diabetes mellitus (GDM) subjects - a preliminary study. Endocrinol Pol 2012; 63: 110-114.
31. Kuzmicki M, Telejko B, Wawrusiewicz-Kurylonek N et al. The expression of suppressor of cytokine signaling 1 and 3 in fat and placental tissue from women with gestational diabetes. Gynecol Endocrinol 2012; 28: 841-844.
32. Telejko B, Kuzmicki M, Zonenberg A et al. Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. Diabetes Res Clin Pract 84: 68-75.
33. Lappas M, Permezel M, Rice GE. Release of proinflammatory cytokines and 8-isoprostane from placenta, adipose tissue, and skeletal muscle from normal pregnant women and women with gestational diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 5627-5633.
34. Winzer C, Wagner O, Festa A et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004; 27: 1721-1727.
35. Zuliani G, Galvani M, Maggio M et al. Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis 2010; 213: 319-324.
36. Nikolajuk A, Kowalska I, Karczewska-Kupczewska M et al. Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome. Diabetes 2010; 59: 1026-1029.
37. Wang Y, Lewis DF, Gu Y et al. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia. Hypertension 2011; 57: 336-342.
38. Febbraio MA gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 2007; 117: 841-849.
39. Sumarac-Dumanovic M, Stevanovic D, Ljubic A et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond.) 2009; 33: 151-156.
40. Zúñiga LA, Shen WJ, Joyce-Shaikh B et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 2010; 185: 6947-6959.